<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ivacaftor</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08820</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ivacaftor (also known as Kalydeco or VX-770) is a drug for the treatment of cystic fibrosis, developed by Vertex Pharmaceuticals and the Cystic Fibrosis Foundation. <span class="caps">FDA</span> approved on January 31, 2012.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08820/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08820/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08820.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08820.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08820.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08820.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08820.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08820">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Kalydeco</td><td>Vertex Pharmaceuticals Incorporated</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>873054-44-5</td></tr><tr><th>Weight</th><td>Average: 392.4907<br>Monoisotopic: 392.209992772</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>28</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>PURKAOJPTOLRMP-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Quinolines and Derivatives</td></tr><tr><th>Subclass</th><td>Quinoline Carboxamides</td></tr><tr><th>Direct parent</th><td>Quinoline Carboxamides</td></tr><tr><th>Alternative parents</th><td>Hydroquinolones; Anilides; Hydroquinolines; Cumenes; Nicotinamides; Aminophenols; Secondary Carboxylic Acid Amides; Enolates; Carboxylic Acids; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>dihydroquinolone; acetanilide; dihydroquinoline; cumene; nicotinamide; pyridine carboxylic acid or derivative; aminophenol; phenol derivative; pyridine; benzene; secondary carboxylic acid amide; carboxamide group; polyamine; enol; enolate; carboxylic acid derivative; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the quinoline carboxamides. These are quinolines in which the quinoline ring system is substituted by one or more carboxamide groups.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.</td></tr><tr><th>Pharmacodynamics</th><td>Ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR). In patients with the G551D mutation, Kalydeco, a pill taken two times a day with fat-containing food, helps the protein made by the CFTR gene function better and as a result, improves lung function and other aspects of CF such as increasing weight gain.</td></tr><tr><th>Mechanism of action</th><td>Cystic fibrosis is caused by any one of several defects in a protein, cystic fibrosis transmembrane conductance regulator, which regulates fluid flow within cells and affects the components of sweat, digestive fluids, and mucus. The defect, which is caused by a mutation in the individual's DNA, can be in any of several locations along the protein, each of which interferes with a different function of the protein. One mutation, G551D, lets the CFTR protein reach the epithelial cell surface, but doesn't let it transport chloride through the ion channel. Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the G551D-CFTR protein.</td></tr><tr><th>Absorption</th><td>The pharmacokinetics of ivacaftor is similar between healthy adult volunteers and patients with CF. When given a single oral dose of 150 mg to healthy subjects, the parameters were as follows:
Tmax = 4 hours;
Cmax = 768 ng/mL;
AUC = 10600 ng*hr/mL;
Time to steady state, 12 hour dosing = 3-5 days 
Following repeated doses for ivacaftor, accumulation occurs. 
When given with a fatty meal, exposure increases 2-4 fold. </td></tr><tr><th>Volume of distribution</th><td><p>The mean apparent volume of distribution (Vz/F) of ivacaftor after a single dose of 275 mg of Ivacaftor in the fed state was similar for healthy subjects and patients with CF. After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean (&#177;SD) for apparent volume of distribution was 353 (122) L.</p></td></tr><tr><th>Protein binding</th><td>Ivacaftor is approximately 99% bound to plasma proteins, primarily to alpha 1-acid glycoprotein and albumin. Ivacaftor does not bind to human red blood cells.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Ivacaftor is extensively metabolized in humans. In vitro and clinical studies indicate that ivacaftor is primarily metabolized by CYP3A. M1 and M6 are the two major metabolites of ivacaftor in humans. M1 has approximately one-sixth the potency of ivacaftor and is considered pharmacologically active. M6 has less than one-fiftieth the potency of ivacaftor and is not considered pharmacologically active.</p></td></tr><tr><th>Route of elimination</th><td>Following oral administration, the majority of ivacaftor (87.8%) is eliminated in the feces after metabolic conversion. The major metabolites M1 and M6 accounted for approximately 65% of the total dose eliminated with 22% as M1 and 43% as M6. There was negligible urinary excretion of ivacaftor as unchanged parent.</td></tr><tr><th>Half life</th><td>12 hours following a single dose</td></tr><tr><th>Clearance</th><td><p>The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.</p></td></tr><tr><th>Toxicity</th><td>There have been no reports of overdose with Ivacaftor. The highest single dose used in a clinical study was 800 mg in a solution formulation without any treatment-related adverse events.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="snp-fx"><thead><tr><th>Interacting Gene/Enzyme</th><th>SNP RS ID</th><th>Allele name</th><th>Defining change</th><th>Effect</th><th>Reference(s)</th></tr></thead><tbody><tr><td>Cystic fibrosis transmembrane conductance regulator<br>Gene symbol: CFTR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P13569" target="_blank">P13569 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs75527207" target="_blank">rs75527207 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele (G &gt; A)</td><td>Cystic Fibrosis patients with the A allele will response to ivacaftor</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/23757359" target="_blank" title='# Hebestreit H, Sauer-Heilborn A, Fischer R, Kading M, Mainz JG: Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation. J Cyst Fibros. 2013 Dec;12(6):599-603. doi: 10.1016/j.jcf.2013.05.006. Epub 2013 Jun 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23757359'>23757359 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr><tr><td>Cystic fibrosis transmembrane conductance regulator<br>Gene symbol: CFTR<br>UniProt: <a class="wishart-link-out" href="http://www.uniprot.org/uniprot/P13569" target="_blank">P13569 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><a class="wishart-link-out" href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=rs75527207" target="_blank">rs75527207 <span class="glyphicon glyphicon-new-window"> </span></a></td><td><span class="wishart wishart-not-available">Not Available</span></td><td>A allele (G &gt; A)</td><td>Cystic Fibrosis patients with the A allele will response to ivacaftor</td><td><span class="citation"><a class="pubmed-link wishart-link-out" data-toggle="tooltip" href="http://www.ncbi.nlm.nih.gov/pubmed/23891399" target="_blank" title='# Van Goor F, Yu H, Burton B, Hoffman BJ: Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J Cyst Fibros. 2013 Jul 23. pii: S1569-1993(13)00113-6. doi: 10.1016/j.jcf.2013.06.008. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23891399'>23891399 <span class="glyphicon glyphicon-new-window"> </span></a></span></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9577</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.6561</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5608</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5474</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7677</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7609</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.945</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7374</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8362</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5686</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5438</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.6456</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9469</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6422</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8404</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5791</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8394
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8149
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2868 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9961
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.819
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>150mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06274">Alvimopan</a></td><td>Decreases levels by P-glycoprotein (MDR-1) efflux transporter. Can significantly increase systemic exposure to P-glycoprotein substrates. </td></tr><tr><td><a href="/drugs/DB06769">Bendamustine</a></td><td>Increases levels of bendamustine by P-glycoprotein (MDR-1) efflux transporter. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. </td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Ivacaftor, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to avoid this combination.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Moderate CYP3A4 inhibitors may increase levels of ivacaftor. Consider dose reduction. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Inhibits p-glycoprotein and affects heptatic metabolism via CYP3A4 therefore increases levels of pazopanib. Consider alternate therapy. </td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01263">Posaconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01323">St. John's Wort</a></td><td>Strong CYP3A4 inducers may decrease levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Ivacaftor, when used in combination with tofacitinib, may increase tofaciitinib concentrations, It is recommended to monitor therapy for signs of toxicity or worsened side effects. </td></tr><tr><td><a href="/drugs/DB08828">Vismodegib</a></td><td>P-glycoprotein inhibitors may increase the chance of adverse drug reactions. Consider using alternative therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Strong CYP3A4 inhibitors may increase levels of ivacaftor. Monitor concomitant therapy closely. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Exposure increases 2- to 4- fold when given with a high fat meal. It is recommended that ivacaftor be given this way. </li></ul></td></tr></tbody></table>